Basic Xalatan Information

• INN (International Nonproprietary Name): Latanoprost
• Brand Names Available In Canada (English): Xalatan (Viatris/Pfizer) 2.5 mL and 5 mL dropper vials; generic latanoprost products from multinational suppliers are available globally and may be stocked in Canada by distributors.
• ATC Code: S01EE01
• Forms & Dosages: Ophthalmic solution 0.005% (0.05 mg/mL) in 2.5 mL and 5 mL multidose vials; preservative‑free ophthalmic solution 0.005% in single‑dose containers.
• Manufacturers In Canada (English): Viatris (Pfizer) markets Xalatan in Canada; other global suppliers include Théa, Sun Pharma, Glenmark (presence in Canada not specified in the source data).
• Registration Status In Canada (English): Xalatan (latanoprost) is listed for the United States and Canada in source packaging data and is marketed as a prescription ophthalmic product.
• OTC / Rx Classification: Prescription Only Medicine (Rx)

Major 2022–2025 Canadian & Global Studies

Worried about what recent studies say about Xalatan and preservative‑free latanoprost?

Recent literature from 2022–2025 emphasises pragmatic trials and pharmacovigilance reports relevant to clinical practice in Canada and internationally.

Multicentre real‑world cohorts and several smaller randomized controlled trials compared preservative‑free latanoprost formulations such as Monoprost® and Iyuzeh® with preserved Xalatan.

Canadian practice audits from provincial glaucoma clinics between 2022 and 2024 reported a clinical trend favouring switches to preservative‑free formulations for patients with ocular surface disease.

Main Outcomes

Do preservative‑free drops lower eye pressure as well as Xalatan?

Across trials, preservative‑free latanoprost achieved non‑inferior intraocular pressure (IOP) lowering compared with benzalkonium chloride (BAK)–containing Xalatan in real‑world cohorts and smaller RCTs.

Adherence and ocular‑surface outcomes tended to improve when patients switched from BAK‑containing drops to preservative‑free options.

These trends affected formulary discussions at provincial levels including Ontario Drug Benefit and BC PharmaCare and influenced hospital ophthalmology formularies.

Safety Observations

Are there new safety warnings?

Most trials and surveillance reports continued to document expected prostaglandin‑class effects such as increased iris pigmentation and eyelash changes.

Reported adverse events were generally mild to moderate and included conjunctival hyperaemia and transient burning on instillation.

Rare macular oedema signals were noted primarily in aphakic or pseudophakic eyes with compromised posterior capsules, consistent with existing cautions.

Systemic adverse events remained rare due to minimal systemic exposure from topical application.

Layman’s Explanation

How does Xalatan help someone with glaucoma?

Latanoprost is an eye drop used once daily to lower high eye pressure by helping the eye drain fluid more effectively.

The usual concentration stocked in Canada is 0.005% (0.05 mg/mL), commonly known as Xalatan or generic latanoprost.

Patients typically apply one drop at night so the medicine works through the day to reduce pressure and protect the optic nerve.

Scientific Breakdown

What’s the pharmacology behind latanoprost?

Latanoprost is a prostaglandin F2α analogue that targets prostaglandin FP receptors in the ciliary body and the uveoscleral outflow pathway.

Activation of these receptors remodels the extracellular matrix and increases uveoscleral outflow, reducing aqueous humour volume and lowering IOP.

Topical dosing results in minimal systemic absorption because corneal esterases convert latanoprost to its active free acid locally.

Once‑daily evening dosing is optimal; dosing more frequently does not increase efficacy and may reduce IOP‑lowering effect.

Available products include Xalatan and various generics in 2.5 mL and 5 mL dropper vials and preservative‑free single‑dose options such as Monoprost® and Iyuzeh®.

Health Canada Approvals (DIN‑Based)

Is Xalatan approved in Canada?

Xalatan is marketed in Canada as latanoprost ophthalmic solution and products carry a Drug Identification Number (DIN) when approved and distributed.

The standard approved indication is open‑angle glaucoma and ocular hypertension at 0.005% once daily.

Preservative‑free versions are increasingly listed internationally and may be added to provincial formularies under special authorizations.

Because Xalatan is a prescription medication, ophthalmic follow‑up and IOP monitoring remain necessary under provincial practice norms.

Notable Off‑Label Trends In Canadian Practice

Do Canadian doctors use latanoprost beyond the label?

Specialist ophthalmologists sometimes use latanoprost off‑label for select paediatric glaucoma cases under close supervision, despite limited paediatric data.

Switching to preservative‑free formulations for patients with ocular surface disease is a common off‑label practice driven by tolerability concerns.

Prostaglandin analogues, including latanoprost, are often chosen as first‑line monotherapy for many patients with open‑angle glaucoma in Canadian practice.

Contraindications such as hypersensitivity and active herpetic keratitis are respected, and caution is used in aphakic or certain pseudophakic eyes because of macular oedema risk.

General Dosing Per Health Canada Monographs

How should patients dose Xalatan?

The standard dose is one drop of latanoprost 0.005% (0.05 mg/mL) in the affected eye(s) once daily, preferably in the evening.

Available packaging includes 2.5 mL and 5 mL multidose vials for Xalatan and generics and single‑dose preservative‑free containers for some brands.

Dosing more than once daily is not recommended because increased frequency does not enhance IOP reduction and may reduce efficacy.

For missed doses, administer the drop the same day if remembered; skip the dose if it is near the time for the next dose and do not double up.

Condition‑Specific Dosing Adjustments

Do older adults or children need dose changes?

Elderly patients typically do not require dose adjustments according to the monograph data.

Pediatric use is limited and often managed under specialist protocols; latanoprost is not routinely recommended for children under 18 without specialist guidance.

Patients who are aphakic or pseudophakic with a torn posterior capsule require careful assessment because of increased macular oedema risk.

Treatment is usually chronic and continued while IOP control remains necessary.

Contraindications (Canadian Advisories)

Who should avoid latanoprost?

Absolute contraindications include known hypersensitivity to latanoprost or any formulation excipient and known herpetic keratitis without specialist oversight.

Relative cautions include active intraocular inflammation such as uveitis, aphakia or pseudophakia with a torn posterior capsule, and severe asthma where monitoring is appropriate.

Adverse Effects (Post‑Market Reports)

What side effects should patients expect?

Common prostaglandin‑class effects include increased iris pigmentation, periocular skin darkening, and eyelash growth.

Patients may experience mild conjunctival hyperaemia, burning, stinging, blurred vision, foreign‑body sensation, or dry eye.

Uncommon but important events reported post‑market include macular oedema, most often in aphakic eyes, and uveitis in susceptible individuals.

Pharmacovigilance between 2022 and 2025 highlighted improved ocular surface outcomes after switching to preservative‑free formulations and continued monitoring for rare macular complications.

Food Interactions Common In Canadian Diet

Will coffee, alcohol, or meals affect latanoprost?

Topical latanoprost has negligible systemic absorption, so there are no clinically relevant food interactions with common Canadian diets including alcohol or coffee intake.

Drug Combinations Flagged By Health Canada

Which medicines need special timing or monitoring?

Systemic drug interactions are rare with latanoprost, but patients on multiple topical ocular therapies should separate drops by 5–10 minutes to avoid washout.

Health Canada cautions about combined use in eyes with active uveitis and advises vigilance when patients use other topical ocular products that may increase preservative exposure or irritation.

There are rare reports of bronchospasm, so monitoring is advised for patients with severe asthma.

Perioperative assessment is recommended when cataract surgery is planned, as prostaglandin analogues may increase macular oedema risk in certain pseudophakic cases.

Canadian Survey Data

What do patients in Canada report about latanoprost?

Surveys and pharmacy reports from 2022–2024 show better ocular comfort and adherence when patients switch from BAK‑preserved Xalatan to preservative‑free latanoprost options such as Monoprost® or Iyuzeh®.

Patients occasionally report cosmetic changes like iris darkening and lash growth; some find lash changes desirable while periocular hyperpigmentation can cause cosmetic concern.

Morning blurring after evening administration is uncommon according to patient feedback collected in pharmacy practice.

Forum & Community Pharmacy Trends

What do Canadian pharmacists see every day?

Community pharmacists in national chains routinely counsel on drop administration technique, storage instructions, and provincial coverage navigation for Ontario Drug Benefit, BC PharmaCare, and RAMQ.

Common counselling points include refrigeration before opening when required, proper instillation technique, and removing contact lenses before application when advised by the prescriber.

Online discussions reflect price sensitivity and interest in generics; pharmacists often guide patients on brand versus generic equivalence and coverage options.

National Pharmacy Chains

Where can patients pick up Xalatan in Canada?

Major chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs commonly stock Xalatan and generics in 2.5 mL and 5 mL dropper vials, with preservative‑free options becoming more available.

Pharmacies provide labeling that includes the DIN and bilingual (EN/FR) patient leaflets as required for Canadian packaging.

Online Pharmacy Availability & Provincial Restrictions

Can patients order Xalatan online in Canada?

Licensed Canadian online pharmacies can dispense prescription latanoprost with a valid prescription and must follow provincial dispensing rules.

Preservative‑free formulations may require special authorization on certain provincial formularies.

In our online pharmacy, xalatan is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Cross‑Border US Comparisons

Is Xalatan cheaper in the United States?

Retail prices can be lower in the US for uninsured buyers, but cross‑border purchases carry import restrictions and potential cold‑chain concerns for products that require refrigeration.

Pharmacies advise verifying return policies and temperature control if considering cross‑border or online purchases from outside Canada.

Comparison Table Of DIN‑Approved Alternatives

How does latanoprost compare with other prostaglandins?

Alternatives available in Canada include bimatoprost (Lumigan generics), travoprost (Travatan Z), and preservative‑free tafluprost (Saflutan in some markets).

IOP efficacy is generally comparable across prostaglandin analogues, with differences mainly in tolerability, preservative content, cost, and specific formulations.

Pros And Cons Checklist

• Latanoprost (Xalatan) — Pros: proven first‑line efficacy, widely available, affordable generics; Cons: some formulations contain BAK preservative and may cause iris/periocular pigmentation.
• Preservative‑Free Latanoprost — Pros: improved ocular surface tolerability for sensitive patients; Cons: may require special authorization and can be more costly.
• Bimatoprost — Pros: similar efficacy and may produce pronounced lash growth; Cons: similar prostaglandin adverse effects and preservative considerations.

Health Canada Approval Process

How are latanoprost products approved in Canada?

Manufacturers submit New Drug Submissions with evidence of safety and efficacy and obtain marketing authorizations that include a Drug Identification Number (DIN) for packaged products.

Post‑market surveillance and adverse event reporting are mandatory for marketed products.

DIN And Bilingual Labelling Rules

What must appear on the packaging in Canada?

Packaging for latanoprost products must display the Health Canada DIN and bilingual labelling in English and French as required for distribution in Canada.

Provincial formularies assess cost‑effectiveness for listing decisions and may require special authorization for preservative‑free options.

Consolidated FAQ

What are common patient questions in Canada?

Q: How often should I use Xalatan?

A: One drop in the affected eye(s) once daily, preferably in the evening; more frequent dosing is not recommended.

Q: Can I switch to preservative‑free latanoprost?

A: Many Canadians switch for ocular surface issues; discuss with your ophthalmologist or pharmacist since provincial coverage varies and special authorization may be required.

Q: Will latanoprost change my eye colour?

A: Increased iris pigmentation is a known and usually permanent effect in some patients, especially those with mixed‑colour irides.

Q: How should I store Xalatan at home?

A: Store refrigerated at 2–8°C before opening if the label directs; after opening store below 25°C and discard according to the label, commonly after 4–6 weeks.

Q: Is it available without a prescription?

A: No — latanoprost is prescription‑only in Canada; obtain it through an ophthalmologist and fill at a licensed pharmacy.

Visual Guide

What should an infographic for Canadian patients include?

Suggested assets are a dosage flowchart showing single daily evening dosing, steps for missed doses, and special population notes such as paediatric caution and no routine elderly adjustment.

A provincial coverage map should highlight Ontario Drug Benefit, BC PharmaCare, and RAMQ differences and note special authorization requirements for preservative‑free products.

Purchase channels visuals should contrast in‑store chains (Shoppers, Rexall, Jean Coutu, London Drugs) with licensed Canadian online pharmacies and cross‑border buying caveats.

Packaging visuals ought to show 2.5 mL/5 mL multidose vials for Xalatan/generics and single‑dose units for Monoprost/Iyuzeh, with bilingual captions and DIN callouts.

Safety checkpoint icons can summarise contraindications, common side effects, and recommended ophthalmologist follow‑up intervals.

Canadian Household Storage Guidelines

How should patients store Xalatan at home?

Follow the label instructions: many Xalatan and generic vials recommend refrigeration at 2–8°C before opening.

After opening, bottles are usually stable at room temperature below 25°C and should be protected from light and discarded after the time indicated on the label, commonly 4–6 weeks.

Preservative‑free single‑dose units are for single use only and should not be saved for multiple doses.

Cold‑Chain Storage Where Applicable

What about transport and travel?

Short transit at ambient Canadian temperatures is generally acceptable for already‑opened bottles if they remain within the labelled time and temperature limits.

For long trips or summer heat, use insulated carriers or keep the product in carry‑on luggage for air travel to avoid exceeding 25°C.

Pharmacies maintain documented temperature control for refrigerated stock, and patients importing products should confirm cold‑chain integrity and compliance with Health Canada rules.

Advice From Canadian Pharmacists

How do pharmacists teach proper instillation?

Wash hands and tilt the head back or lie down, gently pull the lower lid to form a pocket, instil one drop into the pocket, and close the eye for a minute without blinking hard.

Wait 5–10 minutes before instilling other eye drops to avoid dilution or washout.

Avoid touching the bottle tip to the eye to prevent contamination and report new visual changes, severe pain, or signs of inflammation promptly.

Provincial Health Authority Guidance

How often should follow‑up happen?

Provincial guidance sets ophthalmic follow‑up intervals based on glaucoma severity and IOP control, and pharmacists can assist with adherence supports and provincial coverage navigation.

Pharmacists also check that packaging shows the DIN and supply bilingual patient information as required.

Delivery Across Canada (English)

City	Region	Delivery Time
Toronto	Ontario	5-7 days
Montreal	Quebec	5-7 days
Vancouver	British Columbia	5-7 days
Calgary	Alberta	5-7 days
Edmonton	Alberta	5-7 days
Ottawa	Ontario	5-7 days
Winnipeg	Manitoba	5-7 days
Quebec City	Quebec	5-7 days
Halifax	Nova Scotia	5-7 days
Victoria	British Columbia	5-7 days
Hamilton	Ontario	5-9 days
Kitchener	Ontario	5-9 days
Saskatoon	Saskatchewan	5-9 days

Storage And Transport Summary

What are the key storage rules to remember?

Store unopened latanoprost vials refrigerated at 2–8°C when the label instructs, then keep below 25°C after opening and discard according to the product label, typically 4–6 weeks.

Protect the product from light and keep the bottle tightly closed when not in use.

Guidelines For Proper Use

How do pharmacists help patients stick with treatment?

Pharmacists counsel on administration technique, storage, timing relative to other eye drops, and recognition of adverse effects to report to the prescriber.

Patients are reminded that latanoprost is prescription‑only in Canada and that ophthalmologist follow‑up is necessary to monitor intraocular pressure and ocular health.

Pharmacists also assist with provincial coverage paperwork and provide bilingual med sheets and DIN checks at dispensing.

Closing Notes For Patients

What should a patient remember when using Xalatan?

Use one drop in the affected eye(s) once daily in the evening, store according to the label, and keep regular ophthalmology appointments to monitor treatment effect and safety.

Discuss preservative‑free options with the prescriber or pharmacist if you have dry eye or persistent irritation from preserved formulations.

If vision changes, severe eye pain, or signs of inflammation occur, stop the drops and seek urgent ophthalmic assessment.